TO · EDT.TO
Spectral Medical Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Toronto, ON M9C 1C2
- Website
- spectraldx.com
Price · as of 2024-12-31
$1.42
Market cap 378.77M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.74 | +2,064.79% |
| Intrinsic Value(DCF) | $0.28 | -80.28% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.20 | $21.85 | $0.13 | $0.00 | $0.00 |
| 2011 | $0.24 | $26.51 | $0.12 | $0.00 | $0.81 |
| 2012 | $0.20 | $26.30 | $0.01 | $0.00 | $0.00 |
| 2013 | $0.30 | $26.37 | $0.00 | $0.00 | $0.00 |
| 2014 | $0.59 | $27.15 | $0.00 | $0.00 | $0.00 |
| 2015 | $0.79 | $27.13 | $0.00 | $0.00 | $0.00 |
| 2016 | $0.32 | $27.27 | $0.00 | $0.00 | $0.00 |
| 2017 | $0.41 | $27.87 | $0.00 | $0.00 | $0.00 |
| 2018 | $0.38 | $27.41 | $0.01 | $0.00 | $0.00 |
| 2019 | $0.62 | $28.07 | $0.00 | $0.00 | $0.35 |
| 2020 | $0.50 | $29.52 | $0.00 | $0.00 | $0.69 |
| 2021 | $0.36 | $33.71 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.31 | $27.11 | $0.00 | $0.00 | $0.32 |
| 2023 | $0.51 | $26.69 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.71 | $30.74 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Spectral Medical Inc.'s (EDT.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.74
- Current price
- $1.42
- AI upside
- +2,064.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.28
-80.28% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Spectral Medical Inc.
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
- CEO
- Christopher Seto
- Employees
- 29
- Beta
- 0.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.28 ÷ $1.42) − 1 = -80.28% (DCF, example).